Modigraf: new formulation of tacrolimus

Astellas Pharma has launched a new formulation of tacrolimus, Modigraf. It is available as granules for oral suspension that should be administered twice daily.

The oral liquid can be used in paediatric patients because it is suitable for those who are unable to swallow capsules and it allows flexible dosing based on bodyweight.

The preparation has approximately 18% increased bioavailability when compared to Prograf capsules.

Modigraf is licensed for the prophylaxis of transplant rejection in kidney, liver or heart allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressant agents.

Modigraf should only be prescribed by those experienced in immunosuppressive therapy and the management of transplant patients.

The MHRA has recently reinforced that the different formulations of tacrolimus are not interchangeable without careful monitoring. They have advised healthcare professionals to:

  • be aware of the different bioavailabilities of the available oral formulations
  • monitor patients carefully when switching between formulations, or from unlicensed medicines to Modigraf
  • take care to prescribe and dispense the correct product/formulation

View Modigraf drug record

Further information: Astellas

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more